May 2019 - Cernostics

Research Validates Tissue Pathology Test Predicting Progression in Barrett’s Esophagus Published May 24, 2019

Tweet

Objective risk assessment guides surveillance and treatment Patients with Barrett’s esophagus (BE) face a low but consequential risk of progression to esophageal adenocarcinoma, for which treatments are limited. Gastroenterologists need reliable me... Read more

Blinded Independent Validation Study of Tissue Systems Pathology Test in Determining Risk of Progression to Esophageal Cancer in Patients with Barrett’s Esophagus to be Presented at DDW 2019 Published May 8, 2019

Tweet

PITTSBURGH, May 08, 2019 (GLOBE NEWSWIRE) — Cernostics, developer of next-generation cancer diagnostics and prognostics today announced that the results of an independent study validating the use of its TissueCypher Barrett’s Esophagus Assay ... Read more

Customer Service

Mon-Fri 9am-5pm (EST)

Email 412-820-3050

Archive

Customer Service